ClinicalTrials.gg
Active, not recruitingNCT03169985Rosuzet-IVUSUpdated Jul 16, 2025

Randomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque

A Phase 4 interventional study of Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day and Rosuvastatin 20 mg orally once a day in Coronary Artery Disease, sponsored by Samsung Medical Center. Active, not recruiting at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-16.

Sponsored by Samsung Medical Center · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies testing rosuvastatin in Coronary Artery Disease — 2 open to participants now, 5 under way, 1 of them phase 3. rosuvastatin · Coronary Artery Disease.

Planned enrollment
12th of 34
280 · median 175
Started
2017
the only one that year
Phase 4
22 of 34
none open now
Registered
26th of 34
by date

Among the 34 studies testing rosuvastatin in Coronary Artery Disease, this one is the 12th largest by planned enrollment, is the only one that started in 2017, is one of 22 in phase 4, and was the 26th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

2 of the 34 studies testing rosuvastatin in Coronary Artery Disease are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About rosuvastatin

rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing rosuvastatin in Coronary Artery Disease, or all of them as a file.
02

Study summary

The aim of this prospective, open-label, randomized, single center study is to compare the effect of usual dose rosuvastatin plus ezetimibe and high-dose rosuvastatin on modifying atherosclerotic plaque.

Read the detailed description

High-intensity statin therapy have shown improved clinical outcomes compared to placebo or moderate-intensity statin therapy. Based on these results, 2013 American College of Cardiology/American Heart Association(ACC/AHA) guideline on treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults recommended high-intensity statin therapy to patient with coronary artery disease for secondary prevention. However, high-intensity statin therapy was known to increase risk of diabetes mellitus and complication such as hepatotoxicity and myalgia. An alternative to high-intensity statin therapy is reducing the dose of statin and using drug that can improve blood cholesterol level by a different mechanism than statin. Ezetimibe acts on Niemann-Pick C1-like protein then inhibits cholesterol absorption in the intestine, which can reduce low-density lipoprotein(LDL) cholesterol more effectively when administered with statin. In IMPROVE-IT study, simvastatin plus ezetimibe decreased ischemic events more than simvastatin alone in patients with acute coronary syndrome. Although this study could confirm the additional effect of ezetimibe by using the same amount of simvastatin in both groups, it could not compare the effect of statin plus ezetimibe and high dose statin monotherapy. Moreover, there were few data on the efficacy of ezetimibe added to rosuvastatin which is one of the effective statin recommended by various guidelines. One study reported that rosuvastatin 2.5 mg plus ezetimibe 10 mg was superior to rosuvastatin 5 mg monotherapy in reducing LDL cholesterol. Another study reported that adding rosuvastatin 5 mg to ezetimibe 10 mg was more effective than rosuvastatin 5 mg alone in reducing coronary atherosclerotic lesions as measured by intravascular ultrasound. However, the previous studies did not compare the efficacy of combination therapy of usual dose rosuvastatin and ezetimibe to high-dose statin monotherapy. Therefore, investigators aimed to compare the effect of rosuvastatin 10 mg plus ezetimibe 10 mg to rosuvastatin 20 mg alone on the reduction of coronary atherosclerosis in patient with coronary artery disease. If this study shows that the combination of usual dose rosuvastatin and ezetimibe is not inferior to high dose rosuvastatin monotherapy in anti-atherosclerotic effect and safety, it would provide a basis for effective and safe cholesterol treatment.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • Rosuvastatin
  • Ezetimibe
  • Atherosclerotic plaque
  • Intravascular ultrasound
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must be at least 19 years of age
  • Subject with suspected ischemic heart disease undergoing coronary angiography and have intermediate coronary artery stenosis (30-70% by visual estimation) whose revascularization was deferred based on invasive physiologic assessment using fractional flow reserve (>0.80) or intravascular ultrasound (minimum lumen area> 4mm2)
  • Subject can verbally confirm understandings of risks, benefits and treatment alternatives of receiving statin or ezetimibe and he/she or his/her legally authorized representative provides written prior to any study related procedure.

Exclusion criteria

Exclusion Criteria:

  • Subject has calculated \<30 mL/min or dialysis within 30 days.
  • Subject has active liver disease or persistent unexplained serum transaminase elevations (x2 x [ULN]).
  • Subject requires the following concomitant medications: cyclosporine, danazol, niacin, fibrates as concomitant medications
  • Subject requires any of the potent inhibitors, itraconazole, ketoconazole, erythromycin, clarithromycin, and telithromycin, protease inhibitors, nefazodone, probucol, resins, and any drugs.
  • Subject has an allergy/sensitivity to any statin, ezetimibe, and/or their .
  • Subject with history of myopathy or family history of myopathy
  • Untreated hypothyroidism
  • Subject has a history of alcohol and/or drug abuse.
  • Subject is a pregnant or lactating woman, or woman intending to become pregnant.
  • Non-cardiac co-morbid conditions are present with \<2 year or that may result in protocol non-compliance (per site investigator's medical judgment).
  • Unwillingness or inability to comply with the procedures described in this protocol.

    • Eligible patients will be randomly assigned to treatment arms, stratified by diagnosis on admission(acute coronary syndrome or stable ischemic heart disease) and presence of chronic statin use (more than one month)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
280 participants (estimated)

Study arms

  • Active comparator
    Rosuvastatin plus ezetimibe arm

    In patients who have moderate stenosis(30-70%) in coronary artery and deferred to medical treatment by intracoronary physiologic or radiologic test, this arm will be received rosuvastatin 10 mg plus ezetimibe 10 mg qd during 12 months after randomization.

    Drug: Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day

  • Active comparator
    High-dose rosuvastatin monotherapy arm

    In patients who have moderate stenosis(30-70%) in coronary artery and deferred to medical treatment by intracoronary physiologic or radiologic test, this arm will be received rosuvastatin 20 mg qd during 12 months after randomization.

    Drug: Rosuvastatin 20 mg orally once a day

Interventions

  • DrugRosuvastatin 10 mg plus ezetimibe 10 mg orally once a day

    Drug page: RosuvastatinStudies of RosuvastatinRosuvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months by clinical judgement.

    Also known as: Rosuzet tablet 10/10 mg

  • DrugRosuvastatinStudies of RosuvastatinRosuvastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months based by clinical judgement.

    Also known as: Crestor tablet 20 mg

06

What researchers measure

Primary outcomes

  1. Change in percent atheroma volume(PAV) in non-culprit lesions

    PAV is calculated as the percentage of the sum of external elastic membrane(EEM) cross sectional areas(CSA) occupied by total atheroma volume(TAV). TAV was determined by summation of the plaque area, defined as the difference between EEM and lumen CSA, for all evaluable images. These values could be expressed as follows: TAV = ∑(EEM CSA - lumen CSA), PAV = 100 X ∑(EEM CSA - lumen CSA) / ∑EEM CSA

    Time frame: 12 months after index coronary angiography(CAG)

Secondary outcomes

  1. Change in normalized TAV in non-culprit lesions

    The TAV is normalized to the length corresponding to the median number of comparable slices for each treatment group in view of the variability in the length of pullback analyzed between subjects. This value could be expressed as follows: normalized TAV = \[∑(EEM CSA - lumen CSA) / number of images in pullback\] X median number of images in cohort

    Time frame: 12 months after index CAG

  2. Change in indexed TAV

    Indexed TAV is calculated as TAV divided by the length of plaque in each subject. This value could be expressed as follows: Indexed TAV = ∑(EEM CSA - lumen CSA) / plaque length

    Time frame: 12 months after index CAG

  3. Change in fibrous cap thickness by OCT(optical coherence tomography)

    In case that OCT is conducted

    Time frame: 12 months after index CAG

  4. Change in fractional flow reserve(FFR)

    Physiologic index

    Time frame: 12 months after index CAG

  5. Change in coronary flow reserve(CFR)

    Physiologic index

    Time frame: 12 months after index CAG

  6. Change in index of microcirculatory resistance(IMR)

    Physiologic index

    Time frame: 12 months after index CAG

  7. Change in TAV in coronary computed tomography(CT) angiography

    TAV which is measured in CT angiography

    Time frame: 24 months after index CAG

  8. Major adverse cardiovascular events(MACE)

    MACE is defined as a composite of death, myocardial infarction, stroke and revascularization.

    Time frame: 12, 24 and 36 months after index CAG

  9. Change in homeostatic model assessment(HOMA) index

    HOMA index is a method used to quantify insulin resistance. This values could be calculated with fasting plasma glucose and insulin, as follows: HOMA index = glucose X insulin (mg/dL) / 405

    Time frame: 6 months after index CAG

  10. Change in fasting glucose

    For risk of developing diabetes mellitus by statin therapy

    Time frame: 6 and 12 months after index CAG

  11. Change in hemoglobin A1c

    For risk of developing diabetes mellitus by statin therapy

    Time frame: 6 and 12 months after index CAG

  12. Change in lipid profile

    Fasting plasma triglyceride(TG), high-density lipoprotein(HDL), LDL and total cholesterol. These items will be compared separately, and described as a group of lipid profile.

    Time frame: 1, 6 and 12 months after index CAG

  13. Change in high-sensitivity C-reactive protein(hs-CRP)

    hs-CRP

    Time frame: 1 and 12 months after index CAG

  14. Safety endpoint: Number of participants with abnormal laboratory values and adverse events

    1. Creatine kinase(CK) elevation \> 10 times upper limit of normal(ULN) 2. CK elevation \> 10 times ULN on two consecutive visits 3. Hepatic transaminases \> 3 times ULN 4. Hepatic transaminases \> 3 times ULN on two consecutive visits 5. Document reason for discontinuation of study medication These items will be described together as a group of safety endpoint, such as number of participants with abnormal laboratory values and adverse events.

    Time frame: 1 and 12 months after index CAG

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — After publication of first manuscript and trial results, the de-identified data will be shared by permission of principle investigator, when asked.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2017 (actual). Primary completion is estimated for Jan 2027, 114 months after the start.

Of 181 non-industry phase 4 interventional studies under Coronary Artery Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 114 months is above that.

Counting every sponsor, half of 194 studies reached it within 35 months; a quarter within 20 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2017
First posted
May 30, 2017
StartActual
Jul 12, 2017
Primary completionEst.
Jan 28, 2027
CompletionEst.
Jan 28, 2027
Last update
Jul 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03169985
Collaborators
Hanmi Pharmaceutical co., ltd.
Responsible party
Joo-Yong Hahn (Professor, Samsung Medical Center) — Principal investigator
First posted
May 30, 2017
Start date
Jul 12, 2017
Primary completion
Jan 28, 2027 (estimated)
Completion
Jan 28, 2027 (estimated)
Last update
Jul 16, 2025

Study contacts

Joo-Yong Hahn, MD, PhD
study chair · Samsung Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion